Diabetes is a complex disease affecting 26 million people in the US and an estimated 365 million worldwide.

Researchers continue to study and elucidate a vast array of factors within genetics, demographics, ethnicity, and lifestyle habits as contributors to the cause or progression of diabetes and related disorders.

Jenesis is developing a technology portfolio not only through a collaboration with the scientific and clinical advances at Joslin Diabetes Center, but also with other partner companies focused on next-generation products and services targeted towards diabetes management. The company is accelerating the development of select technologies through in vivo validation, preclinical characterization, and strategic alliances for clinical and market development.

The company will also explore the advancement of clinical technologies related to telemedicine, imaging, and e-health by developing collaborations with industry partners and other organizations.